CRCR EXAM TEST BANK LATEST WITH QUESTIONS AND
CORRECT ANSWERS (VERIFIED ANSWERS) 100%
COMPLETE - 229 Questions and Answers Already Graded A+
Premium Exam Tested And Verified
Subject Area Clinical Research and Regulatory Compliance (CRCR)
Description This exam assesses mastery of clinical research regulations, ethical conduct, data
management, and compliance frameworks as per US federal guidelines (FDA,
OHRP, ICH-GCP). It covers IRB operations, informed consent, adverse event
reporting, data integrity, and audit readiness.
Expected Grade A+
Total Questions 229
Duration 3 hours
Learning Outcomes 1. Interpret and apply 21 CFR Part 11, ICH E6(R2), and Common Rule
requirements to complex research scenarios.
2. Evaluate ethical and regulatory implications of protocol deviations,
unanticipated problems, and noncompliance.
3. Design and critique informed consent processes, data management plans, and
monitoring strategies.
Accreditation Designed to meet US university standards for clinical research certification and
aligns with SOCRA/ACRP certification competencies.
Page 1
,1. A Phase III trial uses an electronic data capture system that automatically
populates visit dates from a central scheduling module. During an audit, the sponsor
discovers that the system allowed users to override the auto-populated date with a
manually entered date without generating an audit trail entry. Which regulation is
most directly violated?
A. 21 CFR Part 11 - requirements for electronic records and signatures
B. ICH E6(R2) Section 5.5 - trial management and data handling
C. HIPAA Privacy Rule - de-identification of protected health information
D. FDA's Guidance on Electronic Source Data in Clinical Investigations
Answer: A. 21 CFR Part 11 - requirements for electronic records and signatures
21 CFR Part 11 requires that any change to an electronic record must be recorded in an
audit trail that captures the old value, new value, user ID, and timestamp. The ability to
override auto-populated dates without an audit trail directly violates this requirement.
ICH E6(R2) also addresses data integrity, but the specific regulation for electronic
records is 21 CFR Part 11.
2. A multi-site trial uses a central IRB (sIRB) as required by the NIH Policy. One
site's local IRB requests additional information before ceding review. The sIRB has
already approved the study. How should the lead investigator proceed to maintain
compliance with the Common Rule?
A. Withhold the study from the site until the local IRB completes its review and grants
permission.
B. Proceed with enrollment at the site under the sIRB approval, as the Common Rule
mandates single IRB review for multi-site studies.
C. Submit a modification to the sIRB to incorporate the local IRB's additional requirements,
then re-approve.
D. Discontinue the site's participation because local IRB requirements cannot be overridden
by the sIRB.
Answer: A. Withhold the study from the site until the local IRB completes its
review and grants permission.
The 2018 Common Rule (45 CFR 46.114) requires that each site rely on a single IRB
for federally funded multi-site studies, but the policy does not preempt local IRB
authority. The local IRB may request additional information or impose additional
requirements. The study cannot proceed at that site until the local IRB issues its
approval or cedes review to the sIRB. Option B is incorrect because the Common Rule
does not automatically override local IRB requirements.
Page 2
,3. A researcher proposes to use a validated machine learning algorithm to screen
electronic health records for potential study participants. The algorithm will assign a
risk score and the researcher will only contact patients with scores above a
threshold. Which of the following is the primary regulatory concern?
A. The algorithm may introduce bias against minority populations, violating the Belmont
principle of justice.
B. The researcher must obtain a Certificate of Confidentiality to protect the algorithm as
trade secret.
C. The screening constitutes human subjects research and requires IRB approval before any
data access.
D. The algorithm's use of protected health information requires a HIPAA waiver of
authorization from an IRB or Privacy Board.
Answer: D. The algorithm's use of protected health information requires a HIPAA
waiver of authorization from an IRB or Privacy Board.
Accessing and using PHI for screening purposes, even via an algorithm, generally
requires either individual authorization or a waiver of authorization under HIPAA (45
CFR 164.512(i)). The researcher must obtain a waiver from an IRB or Privacy Board
before accessing the records. Option A is an ethical concern but not the primary
regulatory requirement. Option C is partially correct but the immediate barrier is
HIPAA.
Page 3
, 4. During a study monitoring visit, the CRA notices that the informed consent form
(ICF) used at the site does not include the statement that the study involves research
and a description of the research. The site explains they used an older version
approved before the 2018 Common Rule revisions. Which of the following is
correct?
A. The site may continue using the old ICF as long as the study was approved before January
21, 2019.
B. The site must immediately use the new ICF that includes all required elements under the
revised Common Rule.
C. The site can use the old ICF if the subject signed it before the new rule's effective date and
the study is ongoing.
D. The site must obtain re-consent from all currently enrolled subjects using the new ICF
within 30 days.
Answer: B. The site must immediately use the new ICF that includes all required
elements under the revised Common Rule.
The revised Common Rule (effective January 21, 2019) requires that all ICFs used on
or after that date include the basic elements of informed consent as specified in 45 CFR
46.116. Studies approved before the effective date may continue under the old
regulations, but any new consent forms created after the effective date must comply.
The site is using an old version, so it must update the ICF immediately for all new
enrollments. Re-consent of existing subjects is not required unless the study undergoes
a change that affects their willingness to continue.
Page 4
CORRECT ANSWERS (VERIFIED ANSWERS) 100%
COMPLETE - 229 Questions and Answers Already Graded A+
Premium Exam Tested And Verified
Subject Area Clinical Research and Regulatory Compliance (CRCR)
Description This exam assesses mastery of clinical research regulations, ethical conduct, data
management, and compliance frameworks as per US federal guidelines (FDA,
OHRP, ICH-GCP). It covers IRB operations, informed consent, adverse event
reporting, data integrity, and audit readiness.
Expected Grade A+
Total Questions 229
Duration 3 hours
Learning Outcomes 1. Interpret and apply 21 CFR Part 11, ICH E6(R2), and Common Rule
requirements to complex research scenarios.
2. Evaluate ethical and regulatory implications of protocol deviations,
unanticipated problems, and noncompliance.
3. Design and critique informed consent processes, data management plans, and
monitoring strategies.
Accreditation Designed to meet US university standards for clinical research certification and
aligns with SOCRA/ACRP certification competencies.
Page 1
,1. A Phase III trial uses an electronic data capture system that automatically
populates visit dates from a central scheduling module. During an audit, the sponsor
discovers that the system allowed users to override the auto-populated date with a
manually entered date without generating an audit trail entry. Which regulation is
most directly violated?
A. 21 CFR Part 11 - requirements for electronic records and signatures
B. ICH E6(R2) Section 5.5 - trial management and data handling
C. HIPAA Privacy Rule - de-identification of protected health information
D. FDA's Guidance on Electronic Source Data in Clinical Investigations
Answer: A. 21 CFR Part 11 - requirements for electronic records and signatures
21 CFR Part 11 requires that any change to an electronic record must be recorded in an
audit trail that captures the old value, new value, user ID, and timestamp. The ability to
override auto-populated dates without an audit trail directly violates this requirement.
ICH E6(R2) also addresses data integrity, but the specific regulation for electronic
records is 21 CFR Part 11.
2. A multi-site trial uses a central IRB (sIRB) as required by the NIH Policy. One
site's local IRB requests additional information before ceding review. The sIRB has
already approved the study. How should the lead investigator proceed to maintain
compliance with the Common Rule?
A. Withhold the study from the site until the local IRB completes its review and grants
permission.
B. Proceed with enrollment at the site under the sIRB approval, as the Common Rule
mandates single IRB review for multi-site studies.
C. Submit a modification to the sIRB to incorporate the local IRB's additional requirements,
then re-approve.
D. Discontinue the site's participation because local IRB requirements cannot be overridden
by the sIRB.
Answer: A. Withhold the study from the site until the local IRB completes its
review and grants permission.
The 2018 Common Rule (45 CFR 46.114) requires that each site rely on a single IRB
for federally funded multi-site studies, but the policy does not preempt local IRB
authority. The local IRB may request additional information or impose additional
requirements. The study cannot proceed at that site until the local IRB issues its
approval or cedes review to the sIRB. Option B is incorrect because the Common Rule
does not automatically override local IRB requirements.
Page 2
,3. A researcher proposes to use a validated machine learning algorithm to screen
electronic health records for potential study participants. The algorithm will assign a
risk score and the researcher will only contact patients with scores above a
threshold. Which of the following is the primary regulatory concern?
A. The algorithm may introduce bias against minority populations, violating the Belmont
principle of justice.
B. The researcher must obtain a Certificate of Confidentiality to protect the algorithm as
trade secret.
C. The screening constitutes human subjects research and requires IRB approval before any
data access.
D. The algorithm's use of protected health information requires a HIPAA waiver of
authorization from an IRB or Privacy Board.
Answer: D. The algorithm's use of protected health information requires a HIPAA
waiver of authorization from an IRB or Privacy Board.
Accessing and using PHI for screening purposes, even via an algorithm, generally
requires either individual authorization or a waiver of authorization under HIPAA (45
CFR 164.512(i)). The researcher must obtain a waiver from an IRB or Privacy Board
before accessing the records. Option A is an ethical concern but not the primary
regulatory requirement. Option C is partially correct but the immediate barrier is
HIPAA.
Page 3
, 4. During a study monitoring visit, the CRA notices that the informed consent form
(ICF) used at the site does not include the statement that the study involves research
and a description of the research. The site explains they used an older version
approved before the 2018 Common Rule revisions. Which of the following is
correct?
A. The site may continue using the old ICF as long as the study was approved before January
21, 2019.
B. The site must immediately use the new ICF that includes all required elements under the
revised Common Rule.
C. The site can use the old ICF if the subject signed it before the new rule's effective date and
the study is ongoing.
D. The site must obtain re-consent from all currently enrolled subjects using the new ICF
within 30 days.
Answer: B. The site must immediately use the new ICF that includes all required
elements under the revised Common Rule.
The revised Common Rule (effective January 21, 2019) requires that all ICFs used on
or after that date include the basic elements of informed consent as specified in 45 CFR
46.116. Studies approved before the effective date may continue under the old
regulations, but any new consent forms created after the effective date must comply.
The site is using an old version, so it must update the ICF immediately for all new
enrollments. Re-consent of existing subjects is not required unless the study undergoes
a change that affects their willingness to continue.
Page 4
